• Earlier this month, Ardelyx announced new data from its NORMALIZE and OPTIMIZE trials showing that XPHOZAH (tenapanor) sustainably lowers serum phosphate in chronic kidney disease patients on dialysis without clinically meaningful changes in other serum electrolytes, nutrition markers, body mass, or blood pressure.
• The extended long-term safety and efficacy profile, combined with its first-in-class phosphate absorption inhibition mechanism, could further differentiate XPHOZAH as an add-on therapy for dialysis patients whose phosphate levels remain above guideline targets despite binder treatment or intolerance.
• We will now examine how this reinforcement of XPHOZAH’s long-term safety profile could influence Ardelyx’s investment narrative and future growth assumptions.

Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Ardelyx Investment Narrative Recap

To own Ardelyx, you need to believe that XPHOZAH and IBSRELA can grow into durable, profitable franchises before patent and reimbursement pressures bite. The new NORMALIZE and OPTIMIZE data strengthen XPHOZAH’s long term safety story but do not directly reduce the key near term risk around Medicare and broader payer access, which still looms large over XPHOZAH’s commercial ramp and Ardelyx’s path to profitability.

Among recent developments, the reiteration of 2026 revenue guidance for IBSRELA (US$410 million to US$430 million) and XPHOZAH (US$110 million to US$120 million) is especially relevant. It sets a concrete yardstick against which investors can judge whether these fresh XPHOZAH data help Ardelyx deliver on its current commercial ambition and move closer to breakeven while managing ongoing SG&A and R&D spending.

Yet against this progress, investors still need to weigh the risk that payer decisions and reimbursement shifts could materially affect XPHOZAH’s real world reach and...

Ardelyx's narrative projects $1.0 billion revenue and $317.0 million earnings by 2029. This requires 34.8% yearly revenue growth and a $375.1 million earnings increase from -$58.1 million today.

Uncover how Ardelyx's forecasts yield a $16.33 fair value, a 162% upside to its current price.

Exploring Other Perspectives

Before this safety update, the most optimistic analysts were already modeling revenue of about US$1.1 billion and earnings of roughly US$425.8 million by 2029, which contrasts sharply with concerns about payer consolidation and pricing pressure and shows how differently you and others might interpret new XPHOZAH data going forward.

Explore 9 other fair value estimates on Ardelyx - why the stock might be worth just $10.97!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ardelyx research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Ardelyx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ardelyx's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.